Dr. Baehner previously served as Vice President, Pathology & Oncology Development, Genomic Health, Inc. He is the recipient of numerous awards for his expert research works in related fields. He completed his study at the University of California, San Francisco. His research interests reflect in his wide range of publications in various national and international.
The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.